Printer Friendly

Banyu Receives Japan Manufacturing Approval for Fosamax, Treatment Drug for Osteoporosis.

Tokyo, Japan, Aug 3, 2006 - (JCN) - Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D - generic name: aledronate sodium - on July 26. Fosamax was first launched in Japan in 2001 and since has proven to be an effective drug for patients of post menopausal osteoporosis, indicating an efficiency reduction of cells that cause bone loss.

Fosamax is prescribed to 7 million patients worldwide. Taken once a daily, it can reduce the risk of vertebral compression fracture by 90% and femoral fracture by 51%. It also showed increased drug compliance by having it prescribed once a week.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Aug 4, 2006
Previous Article:INPEX Joins Mine Exploration Project in Western Australia.
Next Article:Citizen to Adopt Pure Holding Company System.

Related Articles
Rebuilding strong bones.
NSAIDS and Fosamax are a bad brew.
Selected ongoing clinical trials #. (Featured CME Topic: Osteoporosis).
Treating osteoporosis.
The patient's page.
Maruho to Distribute STROMECTOL in Japan.
Banyu and Ono Begins Phase III Clinical Trials of a DPP-4 Inhibitor for Type 2 Diabetes Patients.
Banyu, Maruho Receive NHI Approval for Oral Scabies Medication.
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters